Article info

Original research
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

Authors

  • Joan Frigola Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainClinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain PubMed articlesGoogle scholar articles
  • Caterina Carbonell Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainClinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain PubMed articlesGoogle scholar articles
  • Patricia Iranzo Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainOncology Department, Vall d'Hebron University Hospital, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Nuria Pardo Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainOncology Department, Vall d'Hebron University Hospital, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Ana Callejo Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainOncology Department, Vall d'Hebron University Hospital, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Susana Cedres Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainOncology Department, Vall d'Hebron University Hospital, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Alex Martinez-Marti Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainOncology Department, Vall d'Hebron University Hospital, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Alejandro Navarro Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainOncology Department, Vall d'Hebron University Hospital, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Mireia Soleda Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainClinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain PubMed articlesGoogle scholar articles
  • Jose Jimenez Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain PubMed articlesGoogle scholar articles
  • Javier Hernandez-Losa Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Ana Vivancos Cancer Genomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain PubMed articlesGoogle scholar articles
  • Enriqueta Felip Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainClinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainOncology Department, Vall d'Hebron University Hospital, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Ramon Amat Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainClinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ramon Amat; ramat{at}vhio.net; Dr Enriqueta Felip; efelip{at}vhio.net
View Full Text

Citation

Frigola J, Carbonell C, Iranzo P, et al
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

Publication history

  • Accepted February 24, 2022
  • First published April 27, 2022.
Online issue publication 
April 27, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.